Insulet Corp (MEX:PODD) Stock Price, Trades & News

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	0.51
Equity-to-Asset	0.44
Debt-to-Equity	0.73
Debt-to-EBITDA	1.68
Interest Coverage	7.83
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.84	Distress Grey Safe
Beneish M-Score	-2.47	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	26.4
	3-Year EBITDA Growth Rate	63.4
	3-Year EPS without NRI Growth Rate	57.2
	3-Year Book Growth Rate	46.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	26.34
	Future 3-5Y Total Revenue Growth Rate Estimate	19.71

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	89.98
	9-Day RSI	59.8
	14-Day RSI	38.13
	3-1 Month Momentum %	-39.48
	6-1 Month Momentum %	-55.88
	12-1 Month Momentum %	-53.67

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.49
	Quick Ratio	1.81
	Cash Ratio	0.7
	Days Inventory	195.26
	Days Sales Outstanding	58.62
	Days Payable	37.04

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.4
	Shareholder Yield %	7.11

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	71.01
	Operating Margin %	17.49
	Net Margin %	10.44
	EBITDA Margin %	19.45
	FCF Margin %	13.53
	OCF Margin %	21.46
	ROE %	21.64
	ROA %	9.35
	ROIC %	19.16
	3-Year ROIIC %	43.67
	ROC (Joel Greenblatt) %	35.44
	ROCE %	18.55
	Years of Profitability over Past 10-Year	8
	Moat Score	7
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	35.43
	Forward PE Ratio	22.69
	PE Ratio without NRI	28.31
	Shiller PE Ratio	107.3
	Price-to-Owner-Earnings	28.95
	PEG Ratio	0.75
	PS Ratio	3.7
	PB Ratio	8.1
	Price-to-Tangible-Book	9.29
	Price-to-Free-Cash-Flow	27.71
	Price-to-Operating-Cash-Flow	17.36
	EV-to-EBIT	23.47
	EV-to-Forward-EBIT	33.49
	EV-to-EBITDA	19.52
	EV-to-Forward-EBITDA	24.85
	EV-to-Revenue	3.8
	EV-to-Forward-Revenue	3.32
	EV-to-FCF	28.41
	Price-to-GF-Value	0.38
	Price-to-Projected-FCF	5.02
	Price-to-Median-PS-Value	0.35
	Price-to-Peter-Lynch-Fair-Value	1.13
	Price-to-Graham-Number	3.42
	Price-to-Net-Current-Asset-Value	423.14
	Earnings Yield (Greenblatt) %	4.26
	FCF Yield %	3.68
	Forward Rate of Return (Yacktman) %	20.92

Financials (Next Earnings Date:2026-08-07 Est.)

Annual Quarterly TTM

MEX:PODD's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Insulet Corp Executives

Details

GF Value™: MXN7230.04

MEX:PODD

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 8 Good signs with PODD. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil MXN)	53,097.026
	EPS (TTM) (MXN)	78.123
	Beta	0.5593
	3-Year Sharpe Ratio	-0.35
	3-Year Sortino Ratio	-0.45
	Volatility %	48.05
	14-Day RSI	38.13
	14-Day ATR (MXN)	43.436315
	20-Day SMA (MXN)	2617.6585
	12-1 Month Momentum %	-53.67
	52-Week Range (MXN)	2548.13 - 6038.64
	Shares Outstanding (Mil)	69.26

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Insulet Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Insulet Corp Stock Events

Financials Calendars

Event	Date	Price (MXN)
Third quarter earnings conference call for 2026	2026-11-06 08:00	In 129 days
Third quarter earnings results for 2026	2026-11-06	In 128 days
Second quarter earnings conference call for 2026	2026-08-07 08:00	In 38 days
Second quarter earnings results for 2026	2026-08-07	In 37 days
Guidance call for 2026	2026-06-08 10:00	2,664.00 (+0.00%)
William Blair 46th Annual Growth Stock Conference	2026-06-03 14:00	2,664.00 (+0.00%)
General meeting for 2026	2026-05-20 08:00	4,402.00 (+0.00%)
Guidance call for 2026	2026-05-13 09:20	4,402.00 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 08:00	4,402.00 (+0.00%)
First quarter earnings results for 2026	2026-05-06	4,402.00 (+0.00%)

Show

Entries

Insulet Corp Frequently Asked Questions

What is Insulet Corp(MEX:PODD)'s stock price today?

The current price of MEX:PODD is MXN2780.00. The 52 week high of MEX:PODD is MXN6038.64 and 52 week low is MXN2548.13.

When is next earnings date of Insulet Corp(MEX:PODD)?

The next earnings date of Insulet Corp(MEX:PODD) is 2026-08-07 Est..

Does Insulet Corp(MEX:PODD) pay dividends? If so, how much?

Insulet Corp(MEX:PODD) does not pay dividend.

Press Release

	Subject	Date
	Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026	2026-07-01
	Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors	2026-06-25
	Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care	2026-06-06
	Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessi	2026-06-04
	Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor	2026-06-03
	Insulet to Participate in William Blair 46th Annual Growth Stock Conference	2026-05-27
	Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets	2026-05-26
	Insulet to Participate in BofA Securities 2026 Health Care Conference	2026-04-28
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD	2026-04-16
	PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky	2026-04-15

10/Page

Articles on Insulet Corp

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.